Agios Pharmaceuticals (AGIO) Depreciation & Amortization (CF) (2012 - 2026)

Agios Pharmaceuticals' Depreciation & Amortization (CF) history runs 15 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 6.65% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (down 5.75% YoY) and the FY2025 annual result came in at $5.2 million, down 8.42% from the prior year.
• Depreciation & Amortization (CF) was $1.4 million for Q1 2026 at Agios Pharmaceuticals, up from $1.3 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.5 million in Q1 2022 and bottomed at $1.3 million in Q2 2025.
• A 5-year average of $1.6 million and a median of $1.4 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) decreased 27.76% — and 2026, when it gained 6.65%.
• Agios Pharmaceuticals' Depreciation & Amortization (CF) stood at $1.8 million in 2022, then retreated by 22.66% to $1.4 million in 2023, then slipped by 2.57% to $1.4 million in 2024, then retreated by 7.39% to $1.3 million in 2025, then advanced by 7.66% to $1.4 million in 2026.
• Business Quant data shows AGIO's Depreciation & Amortization (CF) at $1.4 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.